Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

X-Rays 4Phantoms, Imaging 4Cyclophosphamide 4fludarabine 3Specimen Handling 3Melphalan 3Magnetic Resonance Spectroscopy 3ulixertinib 2tipifarnib 2tazemetostat 2talazoparib 2selpercatinib 2palbociclib 2ivosidenib 2Vemurafenib 2Temozolomide 2Sirolimus 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2Granulocyte Colony-Stimulating Factor 2Busulfan 2regorafenib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1larotrectinib 1irinotecan sucrosofate 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Pharmacogenomic Variants × Gastrointestinal × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡